{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:37:53Z","timestamp":1787999873806,"version":"build-2784847793"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jns.2022.120275","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T19:57:50Z","timestamp":1651521470000},"page":"120275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Immune checkpoint inhibition in patients with inactive pre-existing neuromuscular autoimmune diseases"],"prefix":"10.1016","volume":"438","author":[{"given":"Andrew","family":"Snavely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo J.","family":"P\u00e9rez-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Sandigursky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata P.","family":"Thawani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jns.2022.120275_bb0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with Cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"268","key":"10.1016\/j.jns.2022.120275_bb0010","first-page":"1","article-title":"Advances in cancer immunotherapy 2019 \u2013 latest trends","volume":"38","author":"Kruger","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.jns.2022.120275_bb0015","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jns.2022.120275_bb0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review","volume":"64","author":"Khan","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"26","key":"10.1016\/j.jns.2022.120275_bb0025","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.jns.2022.120275_bb0030","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jns.2022.120275_bb0035","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jns.2022.120275_bb0040","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jns.2022.120275_bb0045","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ana.25708","article-title":"Severe neurological toxicity of immune checkpoint inhibitors","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann. Neurol."},{"issue":"134","key":"10.1016\/j.jns.2022.120275_bb0050","first-page":"1","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.jns.2022.120275_bb0055","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti\u2013programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.jns.2022.120275_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-019-03273-1","article-title":"Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese adverse drug event report database","volume":"145","author":"Sato","year":"2019","journal-title":"J. Neuro-Oncol."},{"issue":"7","key":"10.1016\/j.jns.2022.120275_bb0065","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/RHU.0000000000001314","article-title":"Risk of toxicity after initiating immune checkpoint inhibitor treatment in patients with rheumatoid arthritis","volume":"27","author":"Efuni","year":"2021","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.jns.2022.120275_bb0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fmed.2020.00137","article-title":"Efficacy and toxicity of immune -checkpoint inhibitors in patients with preexisting autoimmune disorders","volume":"7","author":"Coureau","year":"2020","journal-title":"Front. Med."},{"issue":"9","key":"10.1016\/j.jns.2022.120275_bb0075","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"suppl_4","key":"10.1016\/j.jns.2022.120275_bb0080","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jns.2022.120275_bb0085","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jns.2022.120275_bb0090","article-title":"Immunologic adverse events from immune checkpoint therapy","volume":"101511","author":"Richter","year":"2020","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"4","key":"10.1016\/j.jns.2022.120275_bb0095","doi-asserted-by":"crossref","first-page":"E120","DOI":"10.1002\/mus.26021","article-title":"Refractory myasthenia gravis exacerbation triggered by pembrolizumab","volume":"57","author":"Earl","year":"2018","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jns.2022.120275_bb0100","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/JND-170219","article-title":"Severe exacerbation of myasthenia gravis associated with checkpoint inhibitor immunotherapy","volume":"4","author":"Cooper","year":"2017","journal-title":"J. Neuromuscul. Dis."},{"issue":"1","key":"10.1016\/j.jns.2022.120275_bb0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.25141","article-title":"Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab","volume":"54","author":"Lau","year":"2016","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jns.2022.120275_bb0110","first-page":"119","article-title":"Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis","volume":"78","author":"Maeda","year":"2016","journal-title":"Nagoya J. Med. Sci."},{"issue":"13","key":"10.1016\/j.jns.2022.120275_bb0115","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.2169\/internalmedicine.9153-17","article-title":"Relapsed myasthenia gravis after Nivolumab treatment","volume":"57","author":"Mitsune","year":"2018","journal-title":"Intern. Med."},{"issue":"4","key":"10.1016\/j.jns.2022.120275_bb0120","article-title":"Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: a report of 2 patient cases","volume":"4","author":"Phadke","year":"2016","journal-title":"J. Investig. Med. High Impact Case Rep."},{"issue":"4","key":"10.1016\/j.jns.2022.120275_bb0125","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/CND.0000000000000230","article-title":"Severe relapse of vaccine-induced Guillain-Barr\u00e9 syndrome after treatment with Nivolumab","volume":"20","author":"Yuen","year":"2019","journal-title":"J. Clin. Neuromuscul. Dis."},{"issue":"15 Supplement","key":"10.1016\/j.jns.2022.120275_bb0130","article-title":"Worsening chronic inflammatory demyelinating polyneuropathy after Pembrolizumab treatment of metastatic melanoma: a case report (P1.458)","volume":"90","author":"Shimamoto","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2022.120275_bb0135","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1177\/1352458514549403","article-title":"Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma","volume":"21","author":"Gettings","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2022.120275_bb0140","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2016","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.jns.2022.120275_bb0145","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed Death-1 pathway inhibitors among patients with non-small-cell lung Cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jns.2022.120275_bb0150","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","article-title":"Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders","volume":"67","author":"K\u00e4hler","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.jns.2022.120275_bb0155","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jns.2022.120275_bb0160","first-page":"1","article-title":"Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a patient with metastatic melanoma, psoriasis, and a previous Guillain-Barr\u00e9 syndrome","volume":"2018","author":"Cortellini","year":"2018","journal-title":"Case Rep. Oncol. Med."},{"issue":"1","key":"10.1016\/j.jns.2022.120275_bb0165","doi-asserted-by":"crossref","first-page":"161","DOI":"10.21037\/jgo.2018.09.19","article-title":"Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome","volume":"10","author":"Wang","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"issue":"17","key":"10.1016\/j.jns.2022.120275_bb0170","doi-asserted-by":"crossref","first-page":"e2442","DOI":"10.1212\/WNL.0000000000010632","article-title":"Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes","volume":"95","author":"Sechi","year":"2020","journal-title":"Neurology"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2200137X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2200137X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:58:32Z","timestamp":1758383912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X2200137X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":34,"alternative-id":["S0022510X2200137X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2022.120275","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibition in patients with inactive pre-existing neuromuscular autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2022.120275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120275"}}